Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43850   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis (IPF)

    Summary
    EudraCT number
    2010-024251-87
    Trial protocol
    DE   GB   BE   IE   CZ   IT  
    Global end of trial date
    09 Oct 2013

    Results information
    Results version number
    v1(current)
    This version publication date
    20 Jun 2016
    First version publication date
    01 Aug 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    1199.32
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01335464
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Boehringer Ingelheim
    Sponsor organisation address
    Binger Strasse 173 , Ingelheim am Rhein , Germany,
    Public contact
    QRPE Processes and Systems Coordination Clinical Trial Information Disclosure , Boehringer Ingelheim Pharma GmbH & Co. KG, +1 800243 0127, clintriage.rdg@boehringer-ingelheim.com
    Scientific contact
    QRPE Processes and Systems Coordination Clinical Trial Information Disclosure , Boehringer Ingelheim Pharma GmbH & Co. KG, +1 800243 0127, clintriage.rdg@boehringer-ingelheim.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    21 Nov 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    09 Sep 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    09 Oct 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate a reduction of lung function decline, as measured by a change of the yearly rate of decline of forced vital capacity (FVC).
    Protection of trial subjects
    Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all patients as required.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 May 2011
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety
    Long term follow-up duration
    7 Years
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 41
    Country: Number of subjects enrolled
    Belgium: 34
    Country: Number of subjects enrolled
    China: 68
    Country: Number of subjects enrolled
    Czech Republic: 7
    Country: Number of subjects enrolled
    France: 95
    Country: Number of subjects enrolled
    Germany: 80
    Country: Number of subjects enrolled
    India: 15
    Country: Number of subjects enrolled
    Ireland: 3
    Country: Number of subjects enrolled
    Israel: 25
    Country: Number of subjects enrolled
    Italy: 105
    Country: Number of subjects enrolled
    Japan: 72
    Country: Number of subjects enrolled
    United Kingdom: 61
    Country: Number of subjects enrolled
    United States: 112
    Worldwide total number of subjects
    718
    EEA total number of subjects
    385
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    260
    From 65 to 84 years
    452
    85 years and over
    6

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    All subjects were screened for eligibility to participate in the trial. Subjects attended one specialist site which would then ensure that they (the subjects) met all inclusion/exclusion criteria. Subjects were not to be randomised to trial treatment if any one of the specific entry criteria were violated.

    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Oral administration of placebo matching nintedanib soft gelatine capsules Two patients were randomised to the placebo arm, however those two patients were not treated. Consequently, number of subjects that started is 206 but only 204 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    Oral administration of placebo matching nintedanib soft gelatine capsules twice daily (bid)

    Arm title
    Nintedanib 150mg
    Arm description
    Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.
    Arm type
    Experimental

    Investigational medicinal product name
    Nintedanib 150mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid). In case of lack of tolerability of Nintedanib 150mg bid, the dose could have been reduced to 100mg bid.

    Number of subjects in period 1 [1]
    Placebo Nintedanib 150mg
    Started
    204
    309
    Completed
    174
    260
    Not completed
    30
    49
         Adverse event, serious fatal
    10
    9
         Consent withdrawn by subject
    12
    23
         Reason other than those stated above
    1
    1
         Adverse event, non-fatal
    5
    16
         Protocol deviation
    2
    -
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Baseline characteristics are based on patients who were randomised after successfully completing the screening period and received at least one of the trial medication.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Oral administration of placebo matching nintedanib soft gelatine capsules Two patients were randomised to the placebo arm, however those two patients were not treated. Consequently, number of subjects that started is 206 but only 204 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

    Reporting group title
    Nintedanib 150mg
    Reporting group description
    Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.

    Reporting group values
    Placebo Nintedanib 150mg Total
    Number of subjects
    204 309 513
    Age categorical
    Units: Subjects
    Age continuous
    Treated set (TS): The TS consisted of randomised patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment
    Units: years
        arithmetic mean (standard deviation)
    66.9 ( 8.2 ) 66.9 ( 8.4 ) -
    Gender categorical
    Treated set (TS): The TS consisted of randomised patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment
    Units: Subjects
        Female
    41 58 99
        Male
    163 251 414

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Oral administration of placebo matching nintedanib soft gelatine capsules Two patients were randomised to the placebo arm, however those two patients were not treated. Consequently, number of subjects that started is 206 but only 204 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

    Reporting group title
    Nintedanib 150mg
    Reporting group description
    Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.

    Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks

    Close Top of page
    End point title
    Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
    End point description
    Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. The reported mean represents the adjusted rate.
    End point type
    Primary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [1]
    309 [2]
    Units: mL/year
        arithmetic mean (standard error)
    -239.91 ( 18.709 )
    -114.65 ( 15.327 )
    Notes
    [1] - TS (Only patients with observed cases (OC) values were analysed)
    [2] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Random coefficient regression with fixed effects for treatment, gender, age, height and random effect of patient specific intercept and time. A hierarchical procedure was used in order to demonstrate the superiority of nintedanib over placebo for the primary and two key secondary endpoints. The consecutive steps of the hierarchy were only considered if the previous step was significant at the one-sided 2.5% level and the results were in favour of nintedanib.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [3]
    P-value
    < 0.0001
    Method
    Random coefficient regression
    Parameter type
    Mean difference (final values)
    Point estimate
    125.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    77.68
         upper limit
    172.84
    Variability estimate
    Standard error of the mean
    Dispersion value
    24.209
    Notes
    [3] - Nintedanib 150 mg bid versus Placebo The Roger-Kenward approximation was used to estimate denominators degrees of freedom. Within-patient errors are modeled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-components variance-covariance matrix.

    Secondary: Change From Baseline in Saint George’s Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

    Close Top of page
    End point title
    Change From Baseline in Saint George’s Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
    End point description
    This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    200 [4]
    289 [5]
    Units: points on a scale
        arithmetic mean (standard error)
    4.39 ( 0.96 )
    4.34 ( 0.799 )
    Notes
    [4] - TS (Only patients with observed cases (OC) values were analysed)
    [5] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Total score, baseline SGRQ Total score by- visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    489
    Analysis specification
    Pre-specified
    Analysis type
    superiority [6]
    P-value
    = 0.9657
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.05
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.5
         upper limit
    2.4
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.248
    Notes
    [6] - Nintedanib 150 mg bid versus Placebo. Within-patient errors were modelled by compound symmetry covariance matrix.

    Secondary: Absolute Change From Baseline in FVC Over 52 weeks

    Close Top of page
    End point title
    Absolute Change From Baseline in FVC Over 52 weeks
    End point description
    Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 weeks. Means provided are the adjusted means. Adjusted mean is based on all analysed patients in the model (not only patients with a change from baseline to week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [7]
    307 [8]
    Units: mL
        arithmetic mean (standard error)
    -205 ( 16.544 )
    -95.07 ( 14.375 )
    Notes
    [7] - TS (Only patients with observed cases (OC) values were analysed)
    [8] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC-by visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    511
    Analysis specification
    Pre-specified
    Analysis type
    superiority [9]
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    109.93
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    71.27
         upper limit
    148.59
    Variability estimate
    Standard error of the mean
    Dispersion value
    19.708
    Notes
    [9] - Nintedanib 150 mg bid versus Placebo Within-patient errors are modelled by compound symmetry covariance matrix

    Secondary: Absolute Change From Baseline in FVC (% predicted) over 52 weeks

    Close Top of page
    End point title
    Absolute Change From Baseline in FVC (% predicted) over 52 weeks
    End point description
    Means provided are the adjusted means. Adjusted mean is based on all analysed patients in the model (not only patients with a change from baseline to week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [10]
    307 [11]
    Units: %predicted
        arithmetic mean (standard error)
    -5.98 ( 0.474 )
    -2.76 ( 0.408 )
    Notes
    [10] - TS (Only patients with observed cases (OC) values were analysed)
    [11] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    511
    Analysis specification
    Pre-specified
    Analysis type
    superiority [12]
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    3.22
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.11
         upper limit
    4.33
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.564
    Notes
    [12] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Absolute Categorical Change of FVC (% Predicted) - 5% Threshold

    Close Top of page
    End point title
    Absolute Categorical Change of FVC (% Predicted) - 5% Threshold
    End point description
    Absolute categorical change of FVC (% predicted) by categories at 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within ≤5%).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    165 [13]
    250 [14]
    Units: percentage of participants
    number (not applicable)
        Decrease > 5%
    52.7
    34.8
        Change within ≤ 5%
    41.2
    54
        Increase > 5%
    6.1
    11.2
    Notes
    [13] - Treated Set (for patients with change from baseline in FVC (%predicted) at Week 52)
    [14] - Treated Set (for patients with change from baseline in FVC (%predicted) at Week 52)
    No statistical analyses for this end point

    Secondary: Absolute Categorical Change of FVC (% Predicted) - 10% Threshold

    Close Top of page
    End point title
    Absolute Categorical Change of FVC (% Predicted) - 10% Threshold
    End point description
    Absolute categorical change of FVC (% predicted) by categories at 52 weeks - 10% threshold (decrease by > 10%, increase by >10%, and change within ≤10%.
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    165 [15]
    250 [16]
    Units: percentage of participants
    number (not applicable)
        Decrease > 10%
    29.7
    12.8
        Change within ≤10%
    69.1
    84.4
        Increase > 10%
    1.2
    2.8
    Notes
    [15] - Treated Set (for patients with change from baseline in FVC (%predicted) at Week 52)
    [16] - Treated Set (for patients with change from baseline in FVC (%predicted) at Week 52)
    No statistical analyses for this end point

    Secondary: Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    Proportion of SGRQ Responders at 52 Weeks. Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks.
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [17]
    309 [18]
    Units: percentage of participants
        number (confidence interval 95%)
    24.02 (18.67 to 30.33)
    20.39 (16.27 to 25.23)
    Notes
    [17] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [18] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Logistic regression with terms treatment, baseline SGRQ total score
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [19]
    P-value
    = 0.4298
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    0.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.55
         upper limit
    1.29
    Notes
    [19] - Nintedanib 150 mg bid versus Placebo

    Secondary: Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    202 [20]
    300 [21]
    Units: points on a scale
        arithmetic mean (standard error)
    3.89 ( 1.351 )
    1.56 ( 1.104 )
    Notes
    [20] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [21] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit treatment-by-visit, baseline SGRQ Symptoms component, baseline SGRQ Symptoms component-by-visit and random effect for patient.
    Comparison groups
    Nintedanib 150mg v Placebo
    Number of subjects included in analysis
    502
    Analysis specification
    Pre-specified
    Analysis type
    superiority [22]
    P-value
    = 0.1832
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -2.32
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.74
         upper limit
    1.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.744
    Notes
    [22] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Change From Baseline in SGRQ Impact Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in SGRQ Impact Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
    End point type
    Secondary
    End point timeframe
    baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    202 [23]
    291 [24]
    Units: points on a scale
        arithmetic mean (standard error)
    4.01 ( 1.113 )
    4.87 ( 0.923 )
    Notes
    [23] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [24] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ impact component, baseline SGRQ Impact component-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    493
    Analysis specification
    Pre-specified
    Analysis type
    superiority [25]
    P-value
    = 0.551
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    0.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.97
         upper limit
    3.7
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.446
    Notes
    [25] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix

    Secondary: Change From Baseline in SGRQ Activity Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in SGRQ Activity Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    200 [26]
    295 [27]
    Units: points on scale
        arithmetic mean (standard error)
    5.81 ( 1.103 )
    4.62 ( 0.906 )
    Notes
    [26] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [27] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Activities component, baseline SGRQ Activities component-by-visit and random effect for patient
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    495
    Analysis specification
    Pre-specified
    Analysis type
    superiority [28]
    P-value
    = 0.4049
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -1.19
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.99
         upper limit
    1.61
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.427
    Notes
    [28] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score. The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    200 [29]
    290 [30]
    Units: points on a scale
        arithmetic mean (standard error)
    5.08 ( 0.992 )
    4.3 ( 0.824 )
    Notes
    [29] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [30] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ-I Total score, baseline SGRQ-I Total score-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    490
    Analysis specification
    Pre-specified
    Analysis type
    superiority [31]
    P-value
    = 0.5446
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.78
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.31
         upper limit
    1.75
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.289
    Notes
    [31] - Nintedanib 150mg versus placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    178 [32]
    267 [33]
    Units: points on a scale
        arithmetic mean (standard error)
    7.61 ( 1.376 )
    6.73 ( 1.113 )
    Notes
    [32] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [33] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SOBQ score, baseline SOBQ score-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    445
    Analysis specification
    Pre-specified
    Analysis type
    superiority [34]
    P-value
    = 0.6203
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.35
         upper limit
    2.6
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.77
    Notes
    [34] - Nintedanib 150mg versus placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    202 [35]
    302 [36]
    Units: points on a scale
        arithmetic mean (standard error)
    -0.52 ( 1.4 )
    -0.76 ( 1.136 )
    Notes
    [35] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [36] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline CASA-Q Cough symptoms score, baseline CASA-Q Cough symptoms score-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    504
    Analysis specification
    Pre-specified
    Analysis type
    superiority [37]
    P-value
    = 0.8942
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.24
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.78
         upper limit
    3.3
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.803
    Notes
    [37] - Nintedanib 150 mg versus Placebo. Within- patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    202 [38]
    302 [39]
    Units: points on a scale
        arithmetic mean (standard error)
    -4 ( 1.24 )
    -2.36 ( 1.006 )
    Notes
    [38] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [39] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline CASA-Q Cough impact score, baseline CASA-Q Cough impact score-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    504
    Analysis specification
    Pre-specified
    Analysis type
    superiority [40]
    P-value
    = 0.3042
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    1.64
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.49
         upper limit
    4.77
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.596
    Notes
    [40] - Nintedanib 150 mg versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Proportion of Patient’s Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Proportion of Patient’s Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    Proportion of Patient's Global Impression of Change (PGI-C) responders at 52 weeks. Responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [41]
    309 [42]
    Units: percentage of participants
        number (confidence interval 95%)
    54.9 (48.05 to 61.58)
    60.84 (55.3 to 66.12)
    Notes
    [41] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [42] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Logistic regression with term treatment
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [43]
    P-value
    = 0.1818
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    1.276
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.89
         upper limit
    1.83
    Notes
    [43] - Nintedanib 150mg versus placebo

    Secondary: Time to Death Over 52 Weeks

    Close Top of page
    End point title
    Time to Death Over 52 Weeks
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died over 52 weeks (up to 372 days after randomisation).
    End point type
    Secondary
    End point timeframe
    0-52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [44]
    309 [45]
    Units: percentage of participants
    number (not applicable)
        Failure
    6.4
    4.2
        Censored
    93.6
    95.8
    Notes
    [44] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [45] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [46]
    P-value
    = 0.288
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.63
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.29
         upper limit
    1.36
    Notes
    [46] - Nintedanib 150mg versus Placebo.

    Secondary: Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

    Close Top of page
    End point title
    Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (up to 372 days after randomisation).
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [47]
    309 [48]
    Units: percentage of participants
    number (not applicable)
        Failure
    4.9
    3.2
        Censored
    95.1
    96.8
    Notes
    [47] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [48] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [49]
    P-value
    = 0.3515
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.61
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.25
         upper limit
    1.47
    Notes
    [49] - Nintedanib 150mg versus placebo

    Secondary: Time to On-treatment Death

    Close Top of page
    End point title
    Time to On-treatment Death
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment (up to 28 days after last treatment intake).
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [50]
    309 [51]
    Units: percentage of participants
    number (not applicable)
        Failure
    4.4
    2.6
        Censored
    95.6
    97.4
    Notes
    [50] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [51] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard ratio is based on a Cox´s regression model with terms for treatment, gender, age and height
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [52]
    P-value
    = 0.4869
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.68
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.26
         upper limit
    1.82
    Notes
    [52] - Nintedanib 150mg versus placebo

    Secondary: Time to Death or Lung Transplant Over 52 Weeks

    Close Top of page
    End point title
    Time to Death or Lung Transplant Over 52 Weeks
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (up to 372 days after randomisation).
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [53]
    309 [54]
    Units: percentage of participants
    number (not applicable)
        Failure
    6.9
    5.2
        Censored
    93.1
    94.8
    Notes
    [53] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [54] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [55]
    P-value
    = 0.443
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.36
         upper limit
    1.51
    Notes
    [55] - Nintedanib 150mg versus placebo

    Secondary: Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

    Close Top of page
    End point title
    Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria: FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights). These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [56]
    309 [57]
    Units: percentage of participants
    number (not applicable)
        Failure
    18.1
    14.9
        Censored
    81.9
    85.1
    Notes
    [56] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [57] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [58]
    P-value
    = 0.3558
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.81
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.52
         upper limit
    1.25
    Notes
    [58] - Nintedanib 150mg versus placebo

    Secondary: Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

    Close Top of page
    End point title
    Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
    End point description
    Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    199 [59]
    299 [60]
    Units: percent of oxygen saturation
        arithmetic mean (standard error)
    -0.53 ( 0.15 )
    -0.24 ( 0.129 )
    Notes
    [59] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [60] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline SpO2, baseline SpO2-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    498
    Analysis specification
    Pre-specified
    Analysis type
    superiority [61]
    P-value
    = 0.1138
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    0.29
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.07
         upper limit
    0.64
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.181
    Notes
    [61] - Nintedanib 150mg versus placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Proportion of FVC Responders Using 10% Threshold at 52 Weeks

    Close Top of page
    End point title
    Proportion of FVC Responders Using 10% Threshold at 52 Weeks
    End point description
    FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [62]
    309 [63]
    Units: percentage of participants
        number (confidence interval 95%)
    56.86 (50 to 63.47)
    70.55 (65.24 to 75.36)
    Notes
    [62] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [63] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [64]
    P-value
    = 0.0007
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    1.914
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.32
         upper limit
    2.79
    Notes
    [64] - Nintedanib 150 mg bid versus Placebo

    Secondary: Proportion of FVC Responders Using 5% Threshold at 52 Weeks

    Close Top of page
    End point title
    Proportion of FVC Responders Using 5% Threshold at 52 Weeks
    End point description
    Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [65]
    309 [66]
    Units: percentage of participants
        number (confidence interval 95%)
    38.24 (31.84 to 45.06)
    52.75 (47.18 to 58.25)
    Notes
    [65] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [66] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [67]
    P-value
    = 0.001
    Method
    Regression, Logistic
    Parameter type
    Odds ratio (OR)
    Point estimate
    1.847
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.28
         upper limit
    2.66
    Notes
    [67] - Nintedanib 150 mg bid versus Placebo

    Secondary: Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks: Patient Reported Outcomes (PROs)

    Close Top of page
    End point title
    Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks: Patient Reported Outcomes (PROs)
    End point description
    The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
    End point type
    Secondary
    End point timeframe
    baseline, 12 weeks, 24 weeks and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    203 [68]
    306 [69]
    Units: points on a scale
    arithmetic mean (standard deviation)
        12 weeks (N= 194, 287)
    0.04 ( 15.46 )
    -1.75 ( 16.42 )
        24 weeks (N= 190, 279)
    -0.84 ( 15.37 )
    -0.74 ( 17.92 )
        52 weeks (N=160, 247)
    -5.88 ( 19.17 )
    -2.46 ( 18.92 )
    Notes
    [68] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [69] - Treated Set (Only patients with observed cases (OC) values were analysed)
    No statistical analyses for this end point

    Secondary: Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

    Close Top of page
    End point title
    Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
    End point description
    Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    195 [70]
    286 [71]
    Units: mmol/min/kPa
        arithmetic mean (standard error)
    -0.365 ( 0.075 )
    -0.38 ( 0.0644 )
    Notes
    [70] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [71] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Mixed Model for Repeated Measures with fixed effects for treatment, visit, gender, age, height treatment-by-visit, baseline DLCO (HGB Corrected) [mmol/min/kPa], baseline DLCO (HGB Corrected) [mmol/min/kPa]-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    481
    Analysis specification
    Pre-specified
    Analysis type
    superiority [72]
    P-value
    = 0.865
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.015
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.191
         upper limit
    0.161
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.0896
    Notes
    [72] - Nintedanib 150mg versus placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

    Close Top of page
    End point title
    Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
    End point description
    Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows: Otherwise unexplained clinical features including all of the following: - Unexplained worsening or development of dyspnoea within 30 days - New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit - Exclusion of infection as per routine clinical practice and microbiological studies - Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury. Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks (up to randomisation + 372 days), based on all investigato
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [73]
    309 [74]
    Units: percentage of participants
    number (not applicable)
        Failure
    5.4
    6.1
        Censored
    94.6
    93.9
    Notes
    [73] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [74] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Hazard Ratio is based on a Cox´s regression model with terms for treatment, gender, age and height
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [75]
    P-value
    = 0.6728
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.15
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.54
         upper limit
    2.42
    Notes
    [75] - Nintedanib 150 mg bid versus Placebo

    Secondary: Relative Change From Baseline in FVC Over 52 weeks

    Close Top of page
    End point title
    Relative Change From Baseline in FVC Over 52 weeks
    End point description
    Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [76]
    307 [77]
    Units: percent change
        arithmetic mean (standard error)
    -7.38 ( 0.633 )
    -3.36 ( 0.55 )
    Notes
    [76] - TS (Only patients with observed cases (OC) values were analysed)
    [77] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC-by visit and random effect for patient.
    Comparison groups
    Nintedanib 150mg v Placebo
    Number of subjects included in analysis
    511
    Analysis specification
    Pre-specified
    Analysis type
    superiority [78]
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    4.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.54
         upper limit
    5.5
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.753
    Notes
    [78] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Relative Change From Baseline in FVC (% predicted) over 52 weeks

    Close Top of page
    End point title
    Relative Change From Baseline in FVC (% predicted) over 52 weeks
    End point description
    Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
    End point type
    Secondary
    End point timeframe
    Baseline and 52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [79]
    307 [80]
    Units: percent change
        arithmetic mean (standard error)
    -7.32 ( 0.634 )
    -3.32 ( 0.547 )
    Notes
    [79] - TS (Only patients with observed cases (OC) values were analysed)
    [80] - TS (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.
    Comparison groups
    Placebo v Nintedanib 150mg
    Number of subjects included in analysis
    511
    Analysis specification
    Pre-specified
    Analysis type
    superiority [81]
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.52
         upper limit
    5.48
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.753
    Notes
    [81] - Nintedanib 150 mg bid versus Placebo. Within-patient errors are modelled by compound symmetry covariance matrix.

    Secondary: Risk of an Acute IPF Exacerbation Over 52 Weeks

    Close Top of page
    End point title
    Risk of an Acute IPF Exacerbation Over 52 Weeks
    End point description
    Incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk *100)
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    Placebo Nintedanib 150mg
    Number of subjects analysed
    204 [82]
    309 [83]
    Units: participants/Year*100
        number (not applicable)
    5.6
    6.6
    Notes
    [82] - Treated Set (Only patients with observed cases (OC) values were analysed)
    [83] - Treated Set (Only patients with observed cases (OC) values were analysed)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    Risk ratio was calculated as the ratio of risk of exacerbation in both treatment groups. The log of the risk ratio was assumed to follow a normal distribution with mean 0 and variance equal to the sum of the reciprocals of the number of patients with at least one exacerbation in each treatment arm.
    Comparison groups
    Nintedanib 150mg v Placebo
    Number of subjects included in analysis
    513
    Analysis specification
    Pre-specified
    Analysis type
    superiority [84]
    P-value
    = 0.6793
    Method
    Normal distribution
    Parameter type
    Risk ratio (RR)
    Point estimate
    1.17
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.56
         upper limit
    2.46
    Notes
    [84] - Nintedanib 150mg bid versus placebo

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the first drug administration until 28 days after the last drug administration, up to 425 days
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.1
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Oral administration of placebo matching nintedanib soft gelatine capsules.

    Reporting group title
    Nintedanib 150mg bid
    Reporting group description
    Oral administration of soft gelatine capsules of Nintedanib 150 mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.

    Serious adverse events
    Placebo Nintedanib 150mg bid
    Total subjects affected by serious adverse events
         subjects affected / exposed
    55 / 204 (26.96%)
    96 / 309 (31.07%)
         number of deaths (all causes)
    14
    19
         number of deaths resulting from adverse events
    1
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adenocarcinoma pancreas
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    B-cell lymphoma
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Basal cell carcinoma
         subjects affected / exposed
    3 / 204 (1.47%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder neoplasm
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder transitional cell carcinoma
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastric cancer
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung adenocarcinoma
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    0 / 204 (0.00%)
    4 / 309 (1.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    Metastases to liver
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metastatic neoplasm
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Prostate cancer
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Squamous cell carcinoma
         subjects affected / exposed
    4 / 204 (1.96%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Aortic aneurysm
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypertensive crisis
         subjects affected / exposed
    1 / 204 (0.49%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Microscopic polyangiitis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral ischaemia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chest discomfort
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    2 / 204 (0.98%)
    5 / 309 (1.62%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperthermia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Impaired healing
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Multi-organ failure
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Polyp
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Systemic inflammatory response syndrome
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory failure
         subjects affected / exposed
    2 / 204 (0.98%)
    5 / 309 (1.62%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 5
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Dyspnoea
         subjects affected / exposed
    3 / 204 (1.47%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Idiopathic pulmonary fibrosis
         subjects affected / exposed
    11 / 204 (5.39%)
    20 / 309 (6.47%)
         occurrences causally related to treatment / all
    0 / 15
    0 / 21
         deaths causally related to treatment / all
    0 / 4
    0 / 7
    Pleurisy
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumomediastinum
         subjects affected / exposed
    1 / 204 (0.49%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    3 / 204 (1.47%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pulmonary arterial hypertension
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    3 / 204 (1.47%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary hypertension
         subjects affected / exposed
    6 / 204 (2.94%)
    5 / 309 (1.62%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary mass
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory disorder
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    3 / 204 (1.47%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Substance-induced psychotic disorder
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary function test decreased
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Weight decreased
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Foot fracture
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 204 (0.49%)
    3 / 309 (0.97%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Atrial flutter
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Cardiac arrest
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiomegaly
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cor pulmonale
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary artery occlusion
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coronary artery stenosis
         subjects affected / exposed
    3 / 204 (1.47%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diastolic dysfunction
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    1 / 204 (0.49%)
    4 / 309 (1.29%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 4
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sinus tachycardia
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Balance disorder
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Migraine
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Motor dysfunction
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Polyneuropathy
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    2 / 204 (0.98%)
    3 / 309 (0.97%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Optic ischaemic neuropathy
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Dysphagia
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Haematemesis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Ileus
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestine polyp
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oesophagitis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic cirrhosis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatitis acute
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Cystitis haemorrhagic
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dysuria
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Glomerulonephritis
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure acute
         subjects affected / exposed
    1 / 204 (0.49%)
    3 / 309 (0.97%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal vasculitis
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Chondrocalcinosis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rheumatic disorder
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rheumatoid arthritis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal disorder
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Synovitis
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    2 / 204 (0.98%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    H1N1 influenza
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lobar pneumonia
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    3 / 204 (1.47%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung infection
         subjects affected / exposed
    0 / 204 (0.00%)
    2 / 309 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mycobacterial infection
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peritoneal abscess
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    5 / 204 (2.45%)
    5 / 309 (1.62%)
         occurrences causally related to treatment / all
    1 / 5
    0 / 5
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Sepsis
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    1 / 204 (0.49%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Viral infection
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    1 / 204 (0.49%)
    0 / 309 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 204 (0.00%)
    1 / 309 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo Nintedanib 150mg bid
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    140 / 204 (68.63%)
    262 / 309 (84.79%)
    Investigations
    Weight decreased
         subjects affected / exposed
    12 / 204 (5.88%)
    24 / 309 (7.77%)
         occurrences all number
    12
    25
    Nervous system disorders
    Headache
         subjects affected / exposed
    12 / 204 (5.88%)
    21 / 309 (6.80%)
         occurrences all number
    15
    23
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    13 / 204 (6.37%)
    14 / 309 (4.53%)
         occurrences all number
    14
    17
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    2 / 204 (0.98%)
    26 / 309 (8.41%)
         occurrences all number
    2
    31
    Abdominal pain upper
         subjects affected / exposed
    9 / 204 (4.41%)
    23 / 309 (7.44%)
         occurrences all number
    11
    28
    Constipation
         subjects affected / exposed
    6 / 204 (2.94%)
    17 / 309 (5.50%)
         occurrences all number
    6
    18
    Diarrhoea
         subjects affected / exposed
    38 / 204 (18.63%)
    188 / 309 (60.84%)
         occurrences all number
    50
    333
    Flatulence
         subjects affected / exposed
    1 / 204 (0.49%)
    18 / 309 (5.83%)
         occurrences all number
    1
    19
    Nausea
         subjects affected / exposed
    12 / 204 (5.88%)
    70 / 309 (22.65%)
         occurrences all number
    13
    94
    Vomiting
         subjects affected / exposed
    4 / 204 (1.96%)
    39 / 309 (12.62%)
         occurrences all number
    4
    52
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    26 / 204 (12.75%)
    47 / 309 (15.21%)
         occurrences all number
    30
    51
    Dyspnoea
         subjects affected / exposed
    21 / 204 (10.29%)
    22 / 309 (7.12%)
         occurrences all number
    23
    22
    Idiopathic pulmonary fibrosis
         subjects affected / exposed
    11 / 204 (5.39%)
    10 / 309 (3.24%)
         occurrences all number
    11
    10
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    6 / 204 (2.94%)
    16 / 309 (5.18%)
         occurrences all number
    6
    16
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    16 / 204 (7.84%)
    17 / 309 (5.50%)
         occurrences all number
    17
    19
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    27 / 204 (13.24%)
    35 / 309 (11.33%)
         occurrences all number
    35
    47
    Lower respiratory tract infection
         subjects affected / exposed
    11 / 204 (5.39%)
    16 / 309 (5.18%)
         occurrences all number
    14
    32
    Nasopharyngitis
         subjects affected / exposed
    34 / 204 (16.67%)
    39 / 309 (12.62%)
         occurrences all number
    47
    54
    Upper respiratory tract infection
         subjects affected / exposed
    18 / 204 (8.82%)
    28 / 309 (9.06%)
         occurrences all number
    23
    33
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    14 / 204 (6.86%)
    26 / 309 (8.41%)
         occurrences all number
    15
    26

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    17 Nov 2011
    - ‘Acute IPF exacerbation’ was clarified each time ‘exacerbation’ was mentioned - Procedures and appropriate measures in case of suspicion of a ‘drug induced liver injury’ event were implemented - A re-test was allowed in case a laboratory parameter was found to be abnormal at Visit 1. This was to be conducted if laboratory tests were thought to be a measurement error and not related to the patient’s condition - Patients were to be excluded from the trial if they were not able to follow trial procedures including completion of self administered questionnaires without help - Instructions were included for Investigators on the reporting of DLCO in the eCRF - Addition of the ‘always serious AEs’ according to new BI standards to ensure proper reporting of these events - Inclusion criterion 4 was changed to: ‘Chest HRCT performed within 12 months of Visit 1’, instead of ‘Chest HRCT performed within 12 months of Visit 2’
    04 Sep 2012
    - Addition of exploratory biomarker analyses in order to explore the effect of nintedanib on biomarkers related to IPF pathology and prognostic markers of the disease. Exploratory analyses of samples from patients who gave specific informed consent were performed. Pharmacogenomic analysis was also added - The criterion for poor compliance was defined as a protocol violation

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA